Loading...
•
Mar 31, 2020
Leap Therapeutics Q1 2020 Earnings Report
Reported financial results, noting progress in DKN-01 clinical development and partnership with BeiGene.
Key Takeaways
Leap Therapeutics reported a net loss of $7.2 million for Q1 2020, a decrease compared to $8.6 million for the same period in 2019. The decrease was primarily due to revenue recognized from the BeiGene agreement and a decrease in clinical development expenses.
DKN-01 shows potential as a single agent or in combination with PD-1 antibody therapy or chemotherapy.
Partnership with BeiGene for DKN-01 clinical development and commercialization is progressing.
Site initiation activities are underway for the combination study of DKN-01 plus tislelizumab in gastric or gastroesophageal junction cancer patients.
First patients are expected to be dosed in the second half of the year for the DKN-01 plus tislelizumab combination study.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...